Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8737213 | 0.80 | CCR1 (0.34) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL18820429 | 0.74 | KCNA2 (0.33) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL8737251 | 0.74 | HTR2A (0.31) | CCR1CCR5CCR8HTR2A | |
| SCHEMBL8737765 | 0.74 | CCR1 (0.35) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL1698415 | 0.69 | DRD2 (0.33) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL30110578 | 0.69 | DRD2 (0.33) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL15688334 | 0.69 | NOS2 (0.41) | CCR1CCR5CCR8DRD2HTR2A | |
| SCHEMBL10217310 | 0.69 | CYP2A6 (0.31) | — | |
| SCHEMBL31120928 | 0.68 | CYP1A2 (0.39) | CCR1CCR5CCR8HTR2A | |
| SCHEMBL806473 | 0.68 | CYP1A2 (0.39) | CCR1CCR5CCR8HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |